Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

Introduction
1. Study Objective
2. Scope of the report
3. Market Taxonomy
Study Assumptions and Abbreviations
1. Research Methodology
2. Secondary Research
3. Primary Research
4. SPSS Approach
5. Data Triangulation
Executive Summary
Global Industry Overview
1. Market Overview
2. Regional Synopsis
3. Industry Supply Chain Analysis
4. DROT
  1. Driver
  2. Restraint
  3. Opportunities
  4. Trends
5. Government Regulation: How they would Aid the Business?
6. Competitive Landscape
  1. AstraZeneca PLC
  2. Eli Lilly & Company
  3. Galmed Pharmaceuticals Ltd.
  4. GENFIT S.A.
  5. Novo Nordisk A/S
  6. Novartis AG
  7. PFIZER INC.
  8. Siemens Healthineers AG
  9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
  10. Zydus Lifesciences Limited
7. SWOT Analysis
8. Comparative Analysis Of The Current Technologies
9. Company Share in The Market
10. Analysis of Strategic Initiatives Adopted by Key Players
11. Drug Type Analysis
12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
13. Patent Analysis
14. Recent Developments
15. Industry Risk Assessment
Global Outlook and Projections
1. Global Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
  3. Year-on-Year Growth Forecast (%)
2. Global Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
3. Regional Synopsis (USD Million), 2024-2037
  1. North America, Value (USD Million)
  2. Europe, Value (USD Million)
  3. Asia Pacific, Value (USD Million)
  4. Latin America, Value (USD Million)
  5. Middle East and Africa, Value (USD Million)
Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
North America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. U.S.
    2. Canada
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Europe Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. NORDIC
    7. Russia
    8. Rest of Europe
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Asia Pacific Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. China
    2. Japan
    3. India
    4. Australia
    5. South Korea
    6. Vietnam
    7. Thailand
    8. Singapore
    9. Malaysia
    10. Rest of Asia Pacific
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Latin America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Middle East & Africa Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Global Economic Scenario
1. World Economic Outlook
About Research Nester
1. Our Global Clientele
2. We Serve Clients Across World

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size was valued at USD 4.6 billion in 2024 and is projected to reach a valuation of USD 117 billion by the end of 2037, rising at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics is evaluated at USD 5.9 billion.

The continuous increase in the number of patients with obesity and metabolic syndrome is stimulating the demand for NASH therapeutics and diagnostics. As the need for good treatment increases, diagnostics and therapeutic technologies are witnessing expansion including non-invasive diagnostic methods and tailored treatments. As demand for effective therapies grows, advancements in diagnostics and therapeutics are accelerating, particularly in non-invasive diagnostic tools and targeted therapies. For example, Madrigal Pharmaceuticals' Rezdiffra (resmetirom) received FDA approval in March 2024 for treating non-cirrhotic NASH. This reflects how governments worldwide are promoting and enhancing healthcare infrastructure to support early detection and management of liver diseases, further driving non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market growth.

Furthermore, precision medicine using AI-driven diagnostics is making treatments for NASH personalized and effective. This transformation is further accelerated by strategic partnerships such as Novo Nordisk and Echosens in June 2022 to address the underdiagnosis of NASH. Their collaboration focuses on non-invasive diagnostic tools with the aim of doubling diagnosis rates by 2025. This approach not only attains early detection but also creates lucrative non-alcoholic steatohepatitis therapeutics and diagnostics market opportunities. Such efforts underscore the industry's commitment to improving patient outcomes through innovation.

Frequently Asked Questions (FAQ)

In 2024, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics was USD 4.6 billion.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market size was USD 4.6 billion in 2024 and is projected to reach USD 117 billion by the end of 2037, expanding at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics will be valued at USD 5.9 billion.

Key players in the market are AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc among others.

The retail and specialty pharmacies segment is anticipated to lead the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

North America is anticipated to offer lucrative prospects to companies in the non-alcoholic steatohepatitis (Nash) therapeutics and diagnostics market during the forecast period.

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Browse Key Market Insights with Data Illustration:

Frequently Asked Questions (FAQ)

Subscribe to Our Newsletters

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Browse Key Market Insights with Data Illustration:

Frequently Asked Questions (FAQ)

How big is the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics industry?

What is the outlook for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?

Who are the major players dominating the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics landscape?

Which segment will capture the significant market share for non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics by 2037?

Which region will provide more opportunities for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics business in the coming years?